Zhejiang Tailin BioEngineering Co.,Ltd (SHE:300813)
30.48
+1.51 (5.21%)
Apr 1, 2026, 3:04 PM CST
SHE:300813 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 339.54 | 314.25 | 236.32 | 345 | 253.64 |
Other Revenue | - | 34.75 | 33.54 | 28.88 | 29.61 |
| 339.54 | 349 | 269.86 | 373.88 | 283.25 | |
Revenue Growth (YoY) | -2.71% | 29.33% | -27.82% | 32.00% | 41.46% |
Cost of Revenue | 185.25 | 197.86 | 142 | 180.31 | 111.82 |
Gross Profit | 154.29 | 151.14 | 127.86 | 193.57 | 171.43 |
Selling, General & Admin | 86.18 | 78.17 | 70.72 | 73.22 | 61 |
Research & Development | 57.21 | 62.34 | 58.4 | 64.47 | 55.05 |
Other Operating Expenses | -2.8 | -2.85 | -5.22 | -6.87 | -4.32 |
Operating Expenses | 140.59 | 139.33 | 125.09 | 129.8 | 113.61 |
Operating Income | 13.7 | 11.81 | 2.77 | 63.78 | 57.82 |
Interest Expense | - | -14.78 | -0.59 | -0.88 | -0.13 |
Interest & Investment Income | 4.36 | 11.59 | 11.11 | 10.27 | 9.2 |
Currency Exchange Gain (Loss) | - | 0.14 | 0.3 | -0.06 | -0.02 |
Other Non Operating Income (Expenses) | 2.63 | -0.13 | -0.04 | -0.02 | -0.03 |
EBT Excluding Unusual Items | 20.68 | 8.63 | 13.56 | 73.09 | 66.84 |
Gain (Loss) on Sale of Investments | 0.02 | - | -0.01 | - | 0.05 |
Gain (Loss) on Sale of Assets | - | - | -0 | 0.02 | - |
Asset Writedown | -3.96 | -0.55 | -0.08 | -0.03 | -0.16 |
Other Unusual Items | - | 4.68 | 8.51 | 6.86 | 2.91 |
Pretax Income | 16.74 | 12.77 | 21.98 | 79.95 | 69.64 |
Income Tax Expense | 0.45 | 0.51 | 3.53 | 0.26 | 6.11 |
Earnings From Continuing Operations | 16.29 | 12.25 | 18.45 | 79.69 | 63.53 |
Minority Interest in Earnings | 0.2 | 0.8 | 1.22 | - | - |
Net Income | 16.49 | 13.05 | 19.67 | 79.69 | 63.53 |
Net Income to Common | 16.49 | 13.05 | 19.67 | 79.69 | 63.53 |
Net Income Growth | 26.32% | -33.65% | -75.32% | 25.43% | 31.30% |
Shares Outstanding (Basic) | 118 | 109 | 109 | 108 | 109 |
Shares Outstanding (Diluted) | 118 | 109 | 116 | 112 | 109 |
Shares Change (YoY) | 8.27% | -6.00% | 3.09% | 3.28% | 2.57% |
EPS (Basic) | 0.14 | 0.12 | 0.18 | 0.74 | 0.58 |
EPS (Diluted) | 0.14 | 0.12 | 0.17 | 0.71 | 0.58 |
EPS Growth | 16.67% | -29.41% | -76.06% | 21.45% | 28.01% |
Free Cash Flow | 0.84 | 6.12 | -174.31 | 60.24 | 10.05 |
Free Cash Flow Per Share | 0.01 | 0.06 | -1.51 | 0.54 | 0.09 |
Dividend Per Share | - | 0.100 | 0.100 | 0.231 | 0.144 |
Dividend Growth | - | - | -56.67% | 59.95% | 50.00% |
Gross Margin | 45.44% | 43.31% | 47.38% | 51.77% | 60.52% |
Operating Margin | 4.04% | 3.38% | 1.03% | 17.06% | 20.41% |
Profit Margin | 4.86% | 3.74% | 7.29% | 21.31% | 22.43% |
Free Cash Flow Margin | 0.25% | 1.75% | -64.59% | 16.11% | 3.55% |
EBITDA | 30.37 | 28.17 | 13.96 | 72.88 | 64.47 |
EBITDA Margin | 8.94% | 8.07% | 5.17% | 19.49% | 22.76% |
D&A For EBITDA | 16.67 | 16.36 | 11.19 | 9.1 | 6.65 |
EBIT | 13.7 | 11.81 | 2.77 | 63.78 | 57.82 |
EBIT Margin | 4.04% | 3.38% | 1.03% | 17.06% | 20.41% |
Effective Tax Rate | 2.70% | 4.02% | 16.07% | 0.33% | 8.78% |
Revenue as Reported | - | 349 | 269.86 | 373.88 | 283.25 |
Advertising Expenses | - | 1.66 | 2.19 | 2.44 | 2.94 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.